attruby news - Search News

US FDA approves BridgeBio's drug for rare heart condition

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's blockbuster Vyndaqel.

BridgeBio wins FDA approval for heart disease drug

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the condition in over five years and the company’s first significant commercial product. The drug, known scientifically as acoramidis, will be sold by BridgeBio under the brand name Attruby.

BioPharma Dive · 20h

BridgeBio heart drug approved by FDA, setting up battle with Pfizer

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.

7hon MSN

Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby

The U.S. FDA late Friday approved BridgeBio Pharma’s (NASDAQ:BBIO) lead asset Attruby for the rare heart disorder ...

TipRanks on MSN19h

BridgeBio announces FDA approved Attruby for ATTR-CM patients

Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...

devdiscourse15h

FDA's Game-Changing Approvals and Global Health Alerts

The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...

BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition with Pfizer

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results